Notable Wednesday Option Activity: AXL, GOSS, NOVT

Gossamer Bio (GOSS) saw unusually large options activity with 36,131 contracts traded (~3.6M underlying shares), roughly 73.1% of its one‑month average daily volume (4.9M shares); the $2 strike put expiring Feb 20, 2026 accounted for 12,338 contracts (~1.2M shares). Novanta (NOVT) recorded 3,468 option contracts (~346,800 shares), about 72.7% of its one‑month average daily volume (476,875 shares), led by 1,724 contracts in the $140 call expiring Feb 20, 2026 (~172,400 shares). The flows indicate concentrated, directional options positioning that could produce outsized intraday moves in each equity.

Analysis

Contrarian angles: Consensus may be missing that large GOSS put flow could be portfolio hedging by insiders or block sellers—if not accumulation, the negative price path may be temporary; check blocked/initiated trade flags and insider transactions within 10 days. The NOVT call volume could be takeover speculation; if no M&A within 6–9 months, IV mean-reversion could punish long call buyers. Unintended consequence: aggressive dealer hedging can create short-term feedback loops that overstate fundamental deterioration—use tight, quantitative stops (e.g., 15–25% move threshold) and size accordingly.

Key Decisions for Investors

• Establish a defined-risk bearish position in GOSS: buy Feb 20 2026 $2 / $1 put vertical, size ~0.5% of portfolio, max loss = debit paid; enter only if GOSS IV > 60th percentile and price breaks below $2.50 support, set hard stop to exit if IV compresses >30% or stock closes >$3.50 on three consecutive sessions.
• Establish a defined-risk bullish position in NOVT: buy Feb 20 2026 $140 call, sell $170 call (call spread), size 0.75–1% of portfolio; target >30% upside to $182 by expiry for 2x payoff, cut loss if spread value declines 50% from entry or stock falls below its 50-day MA for 5 sessions.
• Execute a relative-value pair: long NOVT $140/$170 Feb 2026 call spread and long GOSS $2/$1 Feb 2026 put spread as a market-neutral directional spread (net small vega exposure); allocate combined 1–1.25% and rebalance if net IV divergence >20 vol points between tickers.
• Operational monitoring: before initiating, verify aggressor side via tape (sweep prints) and open interest change within 48 hours; monitor FDA/earnings/calendar windows for GOSS over next 30–120 days and any 13D/13G filings for NOVT over next 180 days—adjust or close positions on catalyst confirmation or disconfirmation.